**SUNDAY • MARCH 5, 2017**

3:00 pm – 6:00 pm  
**Welcome Reception in the Lower Lobby at the Mead Center for American Theater**  
Registration and Exhibit Set-Up

**MONDAY • MARCH 6, 2017**

7:00 am – 8:00 am  
Registration and Breakfast in the Exhibit Area, plus Exhibit Setup

8:00 am – 8:30 am  
**Meeting Overview in the Kreeger Theater**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 8:30 am – 9:15 am | **Viral Vectors & Vaccines**  
Kreeger Theater  
View Speaker Abstracts & Bios |
| 9:15 am – 10:00 am | **Cellular Therapies**  
Classroom  
View Speaker Abstracts & Bios |
| 10:00 am – 10:30 am | **Baculovirus Expression Technology**  
Ammerman Rehearsal Hall  
View Speaker Abstracts & Bios |
| 8:30 am – 9:15 am | **Technology Workshop**  
BIA Separations  
High Resolution Monolithic Columns — Enabling Tools for Understanding Viral Structures and Their Purity |
| 9:15 am – 10:00 am | **Technology Workshop**  
Novasep  
What Should be Anticipated and Implemented to Ensure a Successful Process Transfer: A CMO Perspective with Risk Analysis from Analytical to Process Transfer |
| 10:00 am – 10:30 am | **Technology Workshop**  
Vironova AB  
Characterization of Viral Vectors by Electron Microscopy and Image Analysis |
| 10:30 am – 11:00 am | Technology Workshop  
Cellular Therapies  
MilliporeSigma  
Virus Safety for Vaccines, Viral Vectors, and Cell-Based Therapies |
| 11:00 am – 11:30 am | Technology Workshop  
Aldermen  
Critical Raw Materials for AAV and mRNA Therapy: Manufacturing and Quality Considerations |
| 11:30 am – 12:00 noon | Technology Workshop  
Fujifilm Diosynth Biotechnologies Texas, LLC  
Comparison of Adherent Cell Technologies for the Amplification of AAV Virus Stocks and Viral Vectors |
| 12:00 noon – 1:30 pm | **Lunch in the Exhibit Area** (Poster Session from 1:00 – 1:30 pm) |
| 1:30 pm – 2:15 pm | **Technology Workshop**  
Gwendolyn M. Wilmes, PhD  
Dimension Therapeutics  
Potency Assay Development for AAV Vectors |
| 2:15 pm – 3:00 pm | **Technology Workshop**  
Marian Bendik  
Shire  
AAV Vector Quantification Strategy for Clinical Trials |
| 3:00 pm – 3:30 pm | **Afternoon Break in the Exhibit Area** |
| 3:30 pm – 4:15 pm | **Technology Workshop**  
Renukardhya J. Gourapruga, DVM, PhD  
Ohio State University  
Nano-technology-Based Viral Vaccines to Elicit Cross-Protective Immunity in a Pig Model |
| 4:15 pm – 5:00 pm | **Technology Workshop**  
Joseph A. Fraietta, PhD  
University of Pennsylvania  
Predictive Correlates of Response to CD19-Directed T-Cell Therapy |
| 5:00 pm – 6:00 pm | **Plenary Session in the Kreeger Theater**  
Amitabh Deb, PhD  
Novartis Institutes for Biomedical Research  
Stabilizing Lentiviral Vector Formulations for CAR T-Cell Applications |
<p>| 6:00 pm – 8:00 pm | <strong>Reception in the Exhibit Area</strong> |</p>
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 am – 8:30 am</td>
<td><strong>Breakfast in the Exhibit Area</strong></td>
</tr>
</tbody>
</table>
| 8:30 am – 9:15 am | *Suzanna Melotti* - bluebird bio Inc. Physical Characterization of Lentiviral Vectors  
*Allison Hubel, PhD* - University of Minnesota Transforming Preservation of Cells Used Therapeutically: Improved Post-Thaw Function of Mesenchymal Stem Cells  
*João M. N. Vidal* - Instituto de Biologia Experimental e Tecnológica (IBET) - Insect Cell Platforms for Fast Production of Pseudotype Virus-Like Particles for Drug and Vaccine Development |
| 9:15 am – 10:00 am | *Axel Schambach, MD, PhD* - Hannover Medical School - Alpharetroviral Self-Inactivating (SIN) Vectors: Biology, Applications, and Production  
*Cenk Sumen, PhD* - PCT, a Caladris company - Successful Manufacturing of CAR T-Cell Therapies: Challenges and Opportunities  
*Gale E. Smith, PhD* - Novavax, Inc. - Challenges in the Development of a Zika Virus Envelope Dimer (EnvD) Vaccine in Insect Cells |
| 10:00 am – 10:30 am | **Morning Break in the Exhibit Area**                                   |
| 10:30 am – 11:15 am | *Michael L. Roberts, PhD* - Symprotics Ltd Enhancing Viral Vector Manufacturing and Therapeutic Construct Design with Synthetic Promoters  
*Michael C. Holmes*, PhD - Sangamo BioSciences, Inc. - New Zinc Finger Nuclease Architectures for Precision Genome Engineering  
*Linda A. King, PhD* - Oxford Brookes University BacMam Expression Vectors: Applications in Gene Therapy |
| 11:15 am – 12:00 noon | *Matthias Renner, PhD* - Paul-Ehrlich-Institut (PEI) Viral Vector Manufacturing and Control: Regulatory Considerations and Challenges  
*Jeffery N. Odum* - NNE - The Journey to Design Efficient Cell Therapy Manufacturing Assets  
*Dieter Palmberger* - Austrian Centre of Industrial Biotechnology GmbH (ACIB) - Baclovirus-Based Manufacturing of Large Biomolecular Assemblies in Trichoplusia ni Cells |
| 12:00 noon – 1:30 pm | **Lentivirus Reference Standard Working Group Meeting**                   |
| 12:00 noon – 6:00 pm | Free Afternoon with Recommended Group Activity: Guided Walking Tour of Eastern Market and Capitol Hill  
Sponsored by Pall Life Sciences |
| 6:00 pm – 9:00 pm | **Flamenco Banquet in the Molly Smith Study**                           |

**ISBioTech 7th Spring Meeting (continued): TUESDAY • MARCH 7, 2017**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 am – 8:30 am</td>
<td><strong>Breakfast in the Exhibit Area</strong></td>
</tr>
</tbody>
</table>
| 8:30 am – 9:15 am | *Elizabeth Larimore, PhD* - Immune Design Corp. Process Development and Manufacturing of ZEVs, a Lentiviral Vector, for Treatment of Soft Tissue Sarcoma  
*David F. Strongeck, MD* - NIH Clinical Center Chimeric Antigen Receptor T-Cells: Manufacturing Challenges  
*Donald L. Jarvis, PhD* - University of Wyoming Recent Progress Towards Host Cell Improvement in the Baculovirus-Insect Cell System |
| 9:15 am – 10:00 am | *Eduard Ayuso*, DVM, PhD - Université de Nantes Comparative Studies of AAV2 Manufacturing: Mammalian Versus Insect Cells  
*Boro Dropulić, PhD* - Lentigen Technology Inc., a Miltenyi Biotec Company - Integration of Work Flows for the Manufacture of CAR T-Cell Products  
*Nicola A. Burgess-Brown, PhD* - The Structural Genomics Consortium (SGC) - Optimising Baculovirus and BacMam Expression of Human Membrane Proteins |
| 10:00 am – 10:30 am | **Morning Break in the Exhibit Area**                                   |
| 10:30 am – 11:15 am | *Joseph G. Joyce, PhD* - Merck Research Laboratories - Challenges in the Development and Scale-Up of an Attenuated Live Virus Vaccine Candidate for Human Cytomegalovirus Infection  
*Ravi Vyzasatya* - Lonza Walkersville, Inc. - Important Design Considerations for the Development of a cGMP Compliant Manufacturing Process for Cell Therapy Applications  
*David A. Theilmann, PhD* - Agriculture and Agri-Food Canada - The Ins and Outs of Baculovirus Infection: Dissecting the Mechanisms of Nucleocapsid Nuclear Import and Egress |
| 11:15 am – 12:00 noon | *Haifeng Chen, PhD* - Virovec, Inc. Manufacturing Adeno-Associated Virus (AAV) in Insect Cells: Optimizations to Increase Recombinant Baculovirus (rBV) Stability and AAV Yield  
*Martin A. Giedlin, PhD* - Novartis Pharmaceuticals Corporation - Bench to Commercial-Scale Process Development for a CAR T-Cell Therapy  
*M. Javad Aman, PhD* - Integrated Biotherapeutics, Inc. - Virus-Like Particle-Based Vaccines for Filoviruses Produced in the Baculovirus Expression System: Opportunities and Challenges |
| 12:00 noon – 1:30 pm | **Lunch in the Exhibit Area (Poster Session from 1:00 – 1:30 pm)**      |
| 1:30 pm – 2:15 pm | *Rajm S. Vatsan, PhD* - FDA CBER FHA Update on Regulatory Considerations for AAV, CAR T-Cells, and Genome Edited Products  
*Kenny Choi* - Kite Pharma, Inc. - Establishing Process Control for the Production of Autologous CAR T-Cells to Support Multicenter Studies in Leukemia  
*Sergei Zolotukhin, PhD* - University of Florida Direct Head-to-Head Evaluation of Recombinant Adeno-Associated Viral (rAAV) Vectors Manufactured in Human Versus Insect Cells |
| 2:15 pm – 3:00 pm | *Els Verhoeyen* - Ens de Lyon New Lentiviral Vector Pseudotypes for Gene Therapy of Human Hematopoietic Cells  
*Ilya Shestopalov, PhD* - bluebird bio inc. Advanced Cellular Analytics for CD34 Drug Products  
*Robert L. Harrison* - USDA Agricultural Research Service - Baculovirus Expression of Insecticidal Proteins |
| 3:00 pm – 3:30 pm | **Afternoon Break in the Exhibit Area (Exhibit Teardown begins at 3:30 pm)** |
| 3:30 pm – 4:15 pm | *Matthias Hobben, PhD* - Génétathane Large-Scale Manufacturing of AAV Vectors: Scale-Up and Transfer of AAV Production Process for Crigler-Najjar Syndrome Gene Therapy  
*Leyla Diaz, PhD* - BioReziel Corporation Testing Approaches for Cell-Based Therapeutics: Rapid Testing and Regulatory Expectations  
*Brian Passkiet* - Thermo Fisher Scientific A Yeastate-Free Baculovirus-Based Expression System for Enhanced Protein Production in Sf9 Cells |
| 4:15 pm – 5:00 pm | *Nitin Garg* - Applied Genetic Technologies Corporation (AGTC) - Bioreactor Production of Recombinant Herpes Simplex Virus  
*Brian Biscoff* - Cellular Therapy Solutions, LLC Development of a Microfluidic Device for the Removal of Glycerol from Cultured Red Blood Cells  
*Monique M. van Oers, PhD* - Wageningen University - Per Os Infectivity Factors (POI) are Essential Proteins of Oclusion-Derived Viruses (ODVs), the ‘Other’ Baculovirus Particles |
| 5:00 pm – 5:45 pm | *Eevi M. Lipponen* - FinVector Vision Therapies  
OT - Process Development for Large-Scale Lentivirus Production in an Adherent iCELLis 500 Bioreactor |
| 5:45 pm          | **Meeting Adjourns**                                                    |

Due to circumstances beyond the control of meeting organizers, this program is subject to change without notice.